FibroGen

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

FibroGen reports improved financials and readies for new therapy launches

FibroGen's financials improved in Q4 2022, with strong cash reserves.
Strategic focus on new therapy launches and pivotal Phase 3 data.
Progress in commercial manufacturing and readiness for potential launches.
Emphasis on FDA feedback for filing strategies and multiple efficacy endpoints.

FibroGen reports Q1 revenue growth, faces challenges in study results

FibroGen's Q1 2023 performance showed strong revenue but faced challenges with roxadustat's Phase 3 study results.
The company's strengths lie in commercial opportunities, financial stability, and adherence to rigorous data analysis methods.
Challenges include addressing study result concerns and uncertainties in funding tied to clinical milestones.
Opportunities exist in market expansion, especially in IPF treatment, and upcoming Phase 3 trials for pamrevlumab.

FibroGen reports revenue growth amidst challenges and promising opportunities

FibroGen's Q2 2023 performance showed revenue growth and cost reduction efforts.
The company faces challenges in pamrevlumab trials and patent validity issues in China.
However, opportunities lie in upcoming trial readouts and the early-stage oncology pipeline.
FibroGen's strategic pillars and commitment to cost savings are key strengths.

FibroGen reports robust Q3 earnings, eyes expansion amid market challenges

FibroGen's Q3 performance was strong, driven by revenue growth and promising trial results.
The company's strategic pillars and clear pricing strategies position it well for future growth.
While facing challenges like generic competition, FibroGen has opportunities for expansion and market differentiation.
Overall, FibroGen's financial health and pipeline developments indicate a positive outlook for the company.

FibroGen reports robust Q4 performance and eyes expansion opportunities

FibroGen's Q4 2023 earnings call showcased strong performance in China for roxadustat and provided a detailed financial update, addressing key inquiries from analysts.
The company's strategic pillars, emphasis on highest tolerable doses for efficacy, and promising Phase I results position FibroGen well for future growth and drug development.
While challenges exist in interpreting data and prioritizing studies, opportunities in expanding market reach, refining development strategies, and enhancing efficacy markers are evident.
Overall, FibroGen's proactive approach to addressing challenges and exploring opportunities underscores a commitment to innovation and growth in the pharmaceutical sector.

FibroGen reports robust earnings, eyes growth in China and oncology

FibroGen's Q1 2024 earnings call highlighted strong financial performance, promising drug developments, cost efficiencies, and strategic focus on future growth. Despite challenges like market competition and regulatory timelines, the company remains optimistic and proactive in pursuing opportunities for expansion.

FibroGen reports strong Q3 performance in China, eyes growth

FibroGen's Q3 2024 results reflect notable growth in Roxadustat sales in China, cost reductions, and improved financial performance, positioning the company for future success.
Despite facing challenges such as expense management and market uncertainties, FibroGen's strategic pillars, positive outlook, and cash reserves offer resilience and growth potential.
Opportunities lie in market expansion, innovation, and partnerships, signaling a promising trajectory for FibroGen to capitalize on its strengths and drive value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

San Francisco, California--(Newsfile Corp. - April 9, 2021) - Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. The firm is investigating possible securities fraud and certain investors may have valuable claims.Visit: www.hbsslaw.com/investor-fraud/FGENContact An Attorney Now: FGEN@hbsslaw.com844-916-0895FibroGen, Inc. (NASDAQ: FGEN) Investigation: The investigation is focused on FibroGen's presentation of false data of roxadustat to make the anemia drug look safer than it is.In past quarters,

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug

NEW YORK--(BUSINESS WIRE)-- #FederalSecuritiesLaws--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FibroGen, Inc. (NASDAQ: FGEN) on behalf of FibroGen stockholders. Our investigation concerns whether FibroGen has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On April 6, 2021, FibroGen issued a statement “provid[ing] clarification of certain prior disclosur

FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #FGEN--Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN)

Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN)

San Francisco, California--(Newsfile Corp. - April 8, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law claims against FibroGen Inc. (NASDAQ: FGEN) ("FibroGen" or the "Company"). FibroGen is a biopharmaceutical company developing roxadustat, a treatment of anemia in chronic kidney disease ("CKD").On November 8, 2019, the Company issued a press release announcing, "Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic...

Berman Tabacco Investigates Potential Securities Law Violations By California-Based FibroGen Inc. (FGEN) In Connection with Roxadustat "Clarification"

New York, New York--(Newsfile Corp. - April 8, 2021) - Levi & Korsinsky notifies investors that it has commenced an investigation of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) concerning possible violations of federal securities laws. After the market closed on Apr. 6, 2021, FibroGen admitted that the primary cardiovascular safety analysis of its roxadustat Phase 3 program for the treatment

EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of FibroGen, Inc.

Philadelphia, Pennsylvania--(Newsfile Corp. - April 8, 2021) - Berger Montague is investigating potential securities fraud claims against FibroGen, Inc. ("FibroGen" or the "Company") on behalf of investors who purchased FibroGen securities (NASDAQ: FGEN). If you purchased FibroGen securities, have questions concerning your rights or interests, or would like to discuss Berger Montague's investigation, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or Donnell Much at dmuch@bm.net or (215) 875-4667, or contact us at...

FGEN Stock: Berger Montague Investigates Potential Securities Fraud Claims Against FibroGen, Inc. (FGEN) For Manipulating Drug Data

LOS ANGELES--(BUSINESS WIRE)---- $FGEN #FGEN--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

MILWAUKEE, April 8, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against FibroGen (NASDAQ: FGEN).  The investigation results from inaccurate statements Fibrogen may have made regarding its business operations and prospects.

Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc.

NEW YORK--(BUSINESS WIRE)---- $FGEN--The law firm of Kirby McInerney LLP is investigating potential claims against FibroGen Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN). The investigation focuses on the Company and its officers' possible violations of federal securities laws. On April 6, 2021, after the market closed, FibroGen issued a statement “provid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment

INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against FibroGen Inc.

LOS ANGELES--(BUSINESS WIRE)---- $FGEN #investors--The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors

The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $FGEN #FGEN--INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against FibroGen, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

FibroGen shares plunged as much as 43% on Wednesday after the biopharmaceutical developer said there were errors in certain disclosures about safety analyses for its anemia drug candidate roxadustat. In a late Tuesday statement about phase 3 testing data for roxadustat, FibroGen CEO Enrique Conterno said the company "became aware that the primary cardiovascular safety analyses included post-hoc changes to the stratification factors."

FibroGen plunges 43% after the company says there were errors in safety analyses data for its anemia drug candidate (FGEN)

LOS ANGELES--(BUSINESS WIRE)---- $FGEN #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of FibroGen Inc. (“Fibrogen” or the “Company”) (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations of the federal securities laws. If you suffered a loss on your FibroGen investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your c

Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of FibroGen Inc. (FGEN) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)---- $FGEN #CLASSACTION--Law Offices of Howard G. Smith continues its investigation on behalf of FibroGen Inc. (“Fibrogen” or the “Company”) (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations of federal securities laws. On April 6, 2021, after the market closed, FibroGen issued a statement “provid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of FibroGen Inc. (FGEN) on Behalf of Investors

NEW YORK, April 7, 2021 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of FibroGen, Inc. (NASDAQ: FGEN) common stock. FibroGen is a biopharmaceutical company.

Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock

San Francisco, California--(Newsfile Corp. - April 7, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law claims against FibroGen Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). FibroGen is a San Francisco-based biopharmaceutical company developing Roxadustat, a treatment of anemia in chronic kidney disease ("CKD").On November 8, 2019, the Company issued a press release announcing, "Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in...

California Office of Berman Tabacco Launches Investigation into Potential Securities Claims Against FibroGen Inc. (FGEN) In Connection with Roxadustat "Clarification"

Atlanta, Georgia--(Newsfile Corp. - April 7, 2021) - Holzer & Holzer, LLC is investigating whether FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) complied with federal securities laws. On April 6, 2021, FibroGen made an announcement to provide "clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease." The price of FibroGen shares fell following the...

SHAREHOLDER ALERT: Investigation of FibroGen, Inc. Announced by Holzer & Holzer, LLC

The company disclosed a bombshell related to its safety results for lead candidate roxadustat.

Why FibroGen Stock Is Crashing Today

LOS ANGELES--(BUSINESS WIRE)---- $FGEN #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of FibroGen Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your FibroGen investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws,

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of FibroGen Inc. (FGEN) on Behalf of Investors

SAN DIEGO, April 7, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). On April 6, 2021, FibroGen issued a statement that reversed on some of the key safety data used to progress hope for their anemia drug roxadustat.

(FGEN) Alert: Did You Lose Money on Your FibroGen Investment? Contact Johnson Fistel Regarding Investigation

FibroGen's (NASDAQ:FGEN) stock has been falling Wednesday, down 35.34% to a price of $22.25. The stock's volume is currently 2.35 million, which is roughly 176.48% of its recent 30-day volume average of 1.33 million.

Why FibroGen's Stock is Down During Today's Session

BENSALEM, Pa.--(BUSINESS WIRE)---- $FGEN #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of FibroGen Inc. (“Fibrogen” or the “Company”) (NASDAQ: FGEN) investors concerning the Company's possible violations of federal securities laws. On April 6, 2021, after the market closed, FibroGen issued a statement “provid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidne

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of FibroGen Inc. (FGEN) on Behalf of Investors

FibroGen Inc (NASDAQ: FGEN) stock plummeted after hours on Tuesday after a murky disclosure for roxadustat, the company's anemia treatment in chronic kidney disease patients. While preparing for an advisory committee meeting ahead of potential approval of roxadustat, FibroGen said it realized it submitted altered information to the FDA about the drug's cardiovascular safety.

FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat

LOS ANGELES--(BUSINESS WIRE)---- $FGEN #investors--The Law Offices of Frank R. Cruz Announces Investigation of FibroGen Inc. (FGEN) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of FibroGen Inc. (FGEN) on Behalf of Investors

SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has informed the Company late today it has tentatively scheduled a Cardiovascular and Renal Drug Advisory Committee (CRDAC) on July 15, 2021 to review the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis-dependent patients.

News for FibroGen Stock (FGEN)